Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$43.71
+2.0%
$37.93
$21.72
$45.48
$8.35B1.152.50 million shs2.46 million shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$72.65
+1.8%
$72.87
$29.42
$117.33
$7.66B0.151.18 million shs675,773 shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$5.03
+0.1%
$4.44
$2.64
$5.92
$3.18B0.81187,081 shs2.73 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$10.85
-1.1%
$11.14
$8.73
$13.06
$7.47B1.155.71 million shs3.31 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+2.04%-3.14%+16.48%+39.32%+74.82%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
+1.84%-2.26%+4.52%-2.42%+138.20%
Hypermarcas stock logo
HYPMY
Hypermarcas
+0.12%+9.26%+12.53%+39.99%-1.80%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-1.14%-6.51%-3.51%+14.64%+3.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.7029 of 5 stars
4.52.00.03.92.43.30.6
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
4.7525 of 5 stars
3.51.00.04.33.34.21.9
Hypermarcas stock logo
HYPMY
Hypermarcas
N/AN/AN/AN/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
1.554 of 5 stars
3.51.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.93
Moderate Buy$58.8534.64% Upside
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
3.00
Buy$138.2590.30% Upside
Hypermarcas stock logo
HYPMY
Hypermarcas
0.00
N/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.00
Buy$17.5061.36% Upside

Current Analyst Ratings Breakdown

Latest HYPMY, ROIV, CORT, and BBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$67.00 ➝ $76.00
6/25/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $54.00
6/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
6/17/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$49.00
6/9/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$53.00 ➝ $56.00
5/28/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$135.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $145.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$46.00 ➝ $63.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $72.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$221.90M37.40N/AN/A($7.71) per share-5.67
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$675.04M11.41$1.25 per share58.19$6.49 per share11.19
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B2.31$0.47 per share10.64$3.54 per share1.42
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M253.79N/AN/A$7.45 per share1.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$141.21M$1.1662.6339.27N/A19.33%20.40%16.64%8/4/2025 (Estimated)
Hypermarcas stock logo
HYPMY
Hypermarcas
$248.62M$0.2420.94N/A12.51%6.95%3.34%7/23/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)

Latest HYPMY, ROIV, CORT, and BBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/5/2025Q1 2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.17$0.17N/A$0.17$177.93 million$157.21 million
4/29/2025Q1 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million
4/23/2025Q1 2025
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A-$0.04N/A-$0.04N/A$184.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.142.79%N/A58.33%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A

Latest HYPMY, ROIV, CORT, and BBIO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.03452.81%6/30/20257/1/20251/8/2027
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
4.57
4.54
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
3.07
2.96
Hypermarcas stock logo
HYPMY
Hypermarcas
0.63
1.26
0.80
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
33.47
33.47

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
18.20%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.80%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
7.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400189.88 million155.32 millionOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300106.04 million83.99 millionOptionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481633.42 millionN/ANot Optionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million626.10 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$43.70 +0.88 (+2.04%)
Closing price 07/3/2025 03:50 PM Eastern
Extended Trading
$43.12 -0.59 (-1.34%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$72.65 +1.31 (+1.84%)
Closing price 07/3/2025 03:28 PM Eastern
Extended Trading
$72.65 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$5.03 +0.01 (+0.12%)
As of 07/3/2025 12:21 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$10.84 -0.13 (-1.14%)
Closing price 07/3/2025 03:45 PM Eastern
Extended Trading
$10.94 +0.09 (+0.83%)
As of 07/3/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.